Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APO010 in Relapsed/Refractory Multiple Myeloma
NCT03196947Phase 2Terminated
- Sponsor
- Allarity Therapeutics
- Start
- Jun 2017
- Primary completion
- Jan 2020
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of APO010 in multiple myeloma (MM), sponsored by Allarity Therapeutics. Started Jun 2017; status: terminated.
02
Drugs
APO010
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03196947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196947.